In fact, recently, NaPi2b was found to be highly expressed in clear cell carcinoma [19], a subtype of ovarian cancer chemoresistant to platinum-based regimens, thus reinforcing the applicability of Rebmab200 to treat patients who do not respond well to classic chemotherapy. This evidence concerns the gene SLC34A2 and ovarian cancer.